Genomictree
Genomictree (KOSDAQ: 228760) is a Korean molecular diagnostics company commercializing non-invasive, DNA methylation-based cancer early detection tests (EarlyTect® Colon, Bladder, Lung) for hospitals, screening centers, and international distribution partners.
- Company typePublic
- Founded2000
- HeadquartersDaejeon, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genomictree does
Genomictree (KOSDAQ: 228760) is a Korean molecular diagnostics company founded in October 2000 that develops non-invasive cancer early detection tests based on proprietary DNA methylation biomarkers. Its core product line, EarlyTect®, uses cancer-specific methylation biomarkers — SDC2 for colorectal cancer, PENK for bladder cancer, and PCDHGA12 for lung cancer — combined with high-sensitivity LTE-qMSP (Linear Target Enrichment-Quantitative Methylation-Specific PCR) detection technology to identify cancer at early stages through stool, urine, and blood samples. Biomarker discovery is powered by the company's Methyl-Discovery platform (Methyl-DNA Capture, i-MAGIC, Microarray, NGS), and its IP estate spans 580+ registered patents across Korea, the US, Europe, China, and Japan. The company has secured a regulatory portfolio including Korean MFDS Class III approval, CE-IVDR dual certification (January 2026), FDA Breakthrough Device Designation for EarlyTect-B (April 2023), and Class C/B approvals in Malaysia and Singapore.
Genomictree generates revenue through several streams: direct IVD kit sales to Korean hospitals and health screening centers; laboratory testing services performed at its molecular diagnostics center; international supply and distribution agreements with regional partners (ACT Genomics in APAC, Varelli Instituto in Italy/Europe, EDX Medical in the UK); technology transfer and licensing (notably to Shandong Lvkan Orioren Biotechnology in China); and adjacent products including AccuraDTect™ COVID-19 RT-qPCR kits and gtNAT specimen transport media. Its go-to-market is sales-led, combining field sales to major Korean university hospital systems with promotion partnerships to primary care institutions and a US subsidiary (Promis Diagnostics, established September 2019) intended to develop North American LDT services. The company positions its tests as auxiliary/triage diagnostics — for example, EarlyTect-B identifies hematuria patients who require cystoscopy, and EarlyTect-Lung supports decision-making for patients with pulmonary nodules — with quoted clinical metrics of 90.2%/90.2% (sensitivity/specificity) for colorectal cancer, 89.2% sensitivity for high-grade bladder cancer, and 77.8%/92.3% for lung cancer.
Recent strategic emphasis has shifted decisively toward global commercialization. The 2026 CE-IVDR dual certification, the September 2025 inclusion of EarlyTect-B in the American Urological Association's hematuria management guidelines, a January 2026 commitment of approximately 10 billion KRW in infrastructure investment funded through convertible bonds, and supply contracts with EDX Medical (December 2025) and domestic testing institutions (May 2026) all signal an inflection from Korea-centric commercialization to international scale. Beyond diagnostics, Genomictree operates a forward-looking therapeutics platform — the LipoRnaX mRNA delivery system using phytosterol-based LNP formulations with BBB-crossing and CNS-delivery capabilities — and has filed patent applications for next-generation mRNA-based PROTAC and CNS-delivery LNP platforms, diversifying the long-term technology pipeline.
Genomictree firmographics
Firmographics- Name
- Genomictree
- Legal name
- 주식회사 지노믹트리
- Website
- https://genomictree.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Genomictree (KOSDAQ: 228760) is a Korean molecular diagnostics company commercializing non-invasive, DNA methylation-based cancer early detection tests (EarlyTect® Colon, Bladder, Lung) for hospitals, screening centers, and international distribution partners.
- Ownership category
- akta.pro rank
Genomictree industry classification
Industry- Product category
- In Vitro Diagnostics (Molecular Diagnostics)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Genomictree is headquartered
LocationHeadquarters
- HQ city
- Daejeon
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
Genomictree business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- EarlyTect® Cancer Diagnostic Products (IVD Kits): Sale of FDA/Korean MFDS-approved and CE-IVDR certified in vitro diagnostic kits for cancer detection using DNA methylation biomarkers. Products include EarlyTect® Colon Cancer (SDC2), EarlyTect® Bladder Cancer (PENK/PENK methylation), and EarlyTect® Lung Cancer (PCDHGA12). Revenue from direct product sales to hospitals and clinics.
- Diagnostic Testing Services: Laboratory testing services for cancer detection performed by Genomictree's molecular diagnostics center. Samples (stool, urine, blood) are collected from partner hospitals and test providers and analyzed in Genomictree's CLIA-certified lab.
- Technology Transfer / Licensing: Technology transfer agreements for methylation-based cancer detection technology to international partners. Notable transfer to Shandong Lvkan Orien Bio-tech (China) for colorectal cancer companion diagnostics.
- COVID-19 / Infectious Disease Products: AccuraDTect™ COVID-19 RT-qPCR Kit and infectious disease multiplex qPCR products using ASRP-Multiplex technology for pathogen detection.
- Transport Medium / Specimen Collection Products: Sale of gtNAT nucleic acid transport media for specimen preservation and transport.
Go-to-market motion1 record
Distribution channels6 records
Marketing channels6 records
Genomictree product offering
Product offeringCore offering
Genomictree develops, manufactures, and commercializes proprietary DNA methylation biomarker-based in vitro diagnostic (IVD) kits for non-invasive cancer early detection. Its flagship EarlyTect® product line comprises stool-based colorectal cancer screening, urine-based bladder cancer triage, and blood-based lung cancer diagnostic tests, all built around proprietary methylation biomarkers (SDC2, PENK, PCDHGA12). The company also sells laboratory testing services from its Molecular Diagnostics Center, the gtNAT specimen transport medium, the AccuraDTect COVID-19 RT-qPCR kit, and licenses its methylation detection technology to international partners.
Product overview
Genomictree is a molecular diagnostics company specializing in cancer early detection through DNA methylation biomarkers. The company's main product line is EarlyTect®, which includes EarlyTect® Colon Cancer (stool-based), EarlyTect® Bladder Cancer (urine-based), and EarlyTect® Lung Cancer (blood-based) diagnostic tests. Additional products include AccuraTect™ for companion diagnostics, AccuraDTect™ COVID-19 RT-qPCR Kit, and gtNAT transport medium. The company also develops the LipoRnaX™ platform for mRNA delivery using proprietary LNP technology. All EarlyTect® products utilize proprietary DNA methylation detection technology to identify cancer-specific biomarkers for non-invasive cancer diagnostics.
Differentiator
Problem solved
Functional benefit
Brands
- EarlyTect®: Cancer auxiliary diagnostic product line including EarlyTect Colon Cancer, EarlyTect Bladder Cancer, and EarlyTect Lung Cancer. DNA methylation-based non-invasive cancer diagnostic tests.
- AccuraTect™
- AccuraDTect™
- LipoRnaX
- gtNAT
Products and services
- EarlyTect® Colon Cancer Non-invasive stool DNA test for colorectal cancer detection using the SDC2 methylation biomarker. Reported clinical performance of 90.2% sensitivity and 90.2% specificity. Aimed at average/elevated colorectal cancer risk patients reluctant to undergo invasive colonoscopy, and used by hospitals, health screening centers, and clinical labs.
- EarlyTect® Bladder Cancer (EarlyTect-B / BCD) Urine-based bladder cancer triage test for hematuria patients using the PENK methylation biomarker to identify patients requiring cystoscopy. Reported clinical performance of 89.2% sensitivity for high-grade bladder cancer and 87.8% specificity. Received FDA Breakthrough Device Designation (April 2023) and was included in the AUA Guidelines (September 2025).
- AccuraTect™ Cancer companion diagnostic product line under the AccuraTect™ brand for identifying biomarkers to guide targeted therapy decisions in oncology patients.
- AccuraDTect™ COVID-19 RT-qPCR Kit RT-qPCR diagnostic kit for COVID-19 detection targeting the Leader sequence and N gene with reported 98.7% sensitivity and 100% specificity. Uses ASRP-Multiplex technology for pathogen detection.
- gtNAT (Nucleic Acid Transport Medium) Nucleic acid transport medium for specimen preservation and transport at room temperature with 18-month shelf life. Enables infectious agent inactivation and direct nucleic acid extraction without a separate lysis step. Sold as a companion product to Genomictree's diagnostic kits and to clinical laboratories.
- EarlyTect® Lung Cancer Blood cfDNA-based lung cancer diagnostic test for patients with pulmonary nodules using the PCDHGA12 methylation biomarker, with reported 77.8% sensitivity and 92.3% specificity (early-stage I-II sensitivity 62.2%). Currently under MFDS approval process and not yet commercially launched as a released product.
- EarlyTect® Cancer Diagnostic Testing Services Laboratory testing services for cancer detection performed by Genomictree's Molecular Diagnostics Center. Samples (stool, urine, blood) are collected from partner hospitals and test providers and analyzed in the CLIA-certified laboratory. Patients access services through the EarlyTect consumer-facing service website.
- LipoRnaX™ mRNA Delivery Platform Proprietary target-directed LNP-based mRNA delivery platform using a phytosterol-based formulation (ginseng-derived alternatives to cholesterol) for safer and more efficient mRNA delivery. Capabilities include BBB-crossing and CNS delivery, immune cell targeting, and cancer cell-specific delivery. Underpins the company's next-generation nucleic acid therapeutic pipeline.
Quantifiable outcome
- Colorectal cancer detection sensitivity: 90.2% (221/245), specificity: 90.2%; Stage 0-2 sensitivity: 89.1% (114/128)
- +4 more outcomes
Companies that use Genomictree
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Genomictree technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature6 records
Genomictree partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Domestic Testing Institutions (1차 의료기관)corePrimary medical institution promotion partnership for EarlyTect-B bladder cancer testing, signed May 2026 with domestic outsourced testing institutions to drive adoption at primary care level.
- N&B Biotechnology (엔이에스바이오테크놀로지)coreMOU for joint R&D of next-generation nucleic acid therapeutics signed April 2026. Strategic collaboration to develop novel nucleic acid-based therapeutic candidates combining both companies' technologies.
- EDX Medical Ltd. (UK)coreSupply contract for EarlyTect-C colorectal cancer diagnostic products signed December 2025. EDX Medical Ltd. distributes EarlyTect-C products in the UK market.
- ACT GenomicscoreSupply agreement for EarlyTect-C colorectal cancer product signed March 2022. ACT Genomics handles distribution in the Asia Pacific region.
- Varelli InstitutocoreSupply agreement for EarlyTect-C colorectal cancer product signed November 2021 for distribution in Italy and European markets.
- Shandong Lvkan Orioren Biotechnology (산동루캉오리온바이오기술개발유한회사)coreTechnology transfer agreement for colorectal cancer companion diagnostic technology to Chinese partner in May 2021. Partner filed for China NMPA manufacturing approval and milestone payments were received in June 2025.
Scale indicators5 records
Recent moves11 records
Expansion highlights6 records
Genomictree competitors and assessment
Company assessmentDirect peers
- Natera: US-based molecular diagnostics company specializing in cell-free DNA testing for oncology (Signatera for MRD) and reproductive health. Comparable in cell-free DNA/molecular biomarker approach, oncology focus, and pursuit of clinical guideline inclusion for reimbursement.
- Exact Sciences: US-based molecular diagnostics leader with Cologuard, a non-invasive colorectal cancer screening test using stool DNA biomarkers. Directly comparable to Genomictree's EarlyTect Colon Cancer product in indication, mechanism (DNA-based), and target market (screening for average/at-risk populations).
- Gencurix: Korean molecular diagnostics company developing cancer diagnostic tests using proprietary biomarker panels, including lung cancer diagnostics. Comparable in geographic origin (Korea), cancer diagnostics focus, and B2B sales to hospitals and clinical labs.
- Guardant Health: US-based precision oncology company offering liquid biopsy and blood-based cancer diagnostics, including colorectal cancer screening (Shield). Comparable in cancer early detection mission, blood-based diagnostic technology, and pursuit of multi-cancer screening platforms.
- Seegene: Korean molecular diagnostics company developing PCR-based multiplex diagnostic tests, including infectious disease and oncology applications. Comparable in geographic origin (Korea), technology platform (PCR/qPCR-based diagnostics), and B2B distribution to clinical laboratories.
Broad incumbents
- Bio-Techne: US-based life sciences tools and diagnostics company with molecular biology reagents and diagnostic kits, including cancer research tools. Comparable in serving molecular diagnostics applications and providing enabling reagents for methylation-based assays.
- NeoGenomics: US-based oncology-focused clinical laboratory services company offering comprehensive molecular and genetic testing for cancer diagnosis and treatment selection. Comparable in oncology diagnostics focus and serving hospital/clinic customers, though broader in scope.
Emerging players
- DiaCarta: US-based molecular diagnostics company focused on cancer screening and precision diagnostics using proprietary technology platforms. Comparable in cancer diagnostic focus and use of molecular biomarkers, though with broader liquid biopsy applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Genomictree social profiles
Digital presenceGenomictree compliance and trust
Trust signalCompliance4 records
Genomictree financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genomictree leadership team
Management profileNumber of profiles
Profiles6 records
Genomictree subsidiaries and ownership
Company hierarchySubsidiaries1 record
Genomictree funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genomictree M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genomictree
What does Genomictree do?
Genomictree develops, manufactures, and commercializes proprietary DNA methylation biomarker-based in vitro diagnostic (IVD) kits for non-invasive cancer early detection. Its flagship EarlyTect® product line comprises stool-based colorectal cancer screening, urine-based bladder cancer triage, and blood-based lung cancer diagnostic tests, all built around proprietary methylation biomarkers (SDC2, PENK, PCDHGA12). The company also sells laboratory testing services from its Molecular Diagnostics Center, the gtNAT specimen transport medium, the AccuraDTect COVID-19 RT-qPCR kit, and licenses its methylation detection technology to international partners.
Is Genomictree a public or private company?
Genomictree is a public company. It is classified as public and is currently operating.
When was Genomictree founded?
Genomictree was founded in 2000. It employs 51 to 100 people.
Where is Genomictree based?
Genomictree is headquartered in Daejeon, South Korea, in the Asia region.
How does Genomictree make money?
Five revenue lines are on record. EarlyTect® Cancer Diagnostic Products (IVD Kits) is the primary driver. The others are diagnostic Testing Services, technology Transfer / Licensing, COVID-19 / Infectious Disease Products and transport Medium / Specimen Collection Products.
Who are Genomictree's main competitors?
Direct peers on record are Natera, Exact Sciences, Gencurix, Guardant Health and Seegene. Broad incumbents are Bio-Techne and NeoGenomics. DiaCarta is listed as an emerging player.
Does Genomictree have an API?
No public API is recorded for Genomictree.
What industry is Genomictree in?
Genomictree's product category is In Vitro Diagnostics (Molecular Diagnostics). Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.